Intrinsiqq
MBX Biosciences, Inc. logo

MBX Biosciences, Inc. Financials

MBX

⊜ Compare

All currency values in $ millions unless otherwise noted

Income Statement
DEC 2025
~3.4:1 split
DEC 2024
~10.4:1 split
DEC 2023
General & Administrative$19$11$7
Research & Development$79$57$29
Total Operating Expenses$98$68$35
Operating Income-$98-$68-$35
EBT (Earnings Before Tax)-$87-$62–
Income Tax Expense$0$0$0
Net Income
Net Income-$87-$62-$33
EPS (Basic)-$2.38-$5.82-$31.96
EPS (Diluted)-$2.38-$5.82-$31.96
Weighted Avg Shares (Basic)36.5M10.6M1.0M
Weighted Avg Shares (Diluted)36.5M10.6M1.0M
Shares Outstanding36.5M10.6M1.0M

MBX Biosciences (MBX) financials: revenue, profit and margins

MBX Biosciences (MBX) generated about n/a in revenue and -$104 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is MBX Biosciences profitable?+

MBX Biosciences reported about -$104 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 3 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 7 Aug 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with MBX

CompareIntrinsic value
KRROKorro Bio Inc.
$16.62+4.79%10
WHWKWhitehawk Therapeutics, Inc.
$3.15+1.61%10
FHTXFoghorn Therapeutics Inc.
$2.10-1.41%40
NATRNature's Sunshine Products Inc.
$12.84+6.38%70
EVMNEvommune, Inc.
$6.04+1.68%35
VSTMVerastem Inc.
$9.85+0.82%40
ARCTArcturus Therapeutics Holdings Inc.
$10.87+13.94%13
XERSXeris Biopharma Holdings, Inc.
$10.46+1.06%30

Held by ETFs

MBX is in 44 US ETFs. The largest of them, with MBX's weight in each:

Spot a number that looks wrong? Check it in MBX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MBX

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.